|
The Division is currently
soliciting ideas for Programming for the 2010 EB meetings in New
Orleans. If you have an idea for a symposium or for divisional
programming, please
CLICK HERE |
Membership is not
automatic...
Becoming a
member of the Behavioral Pharmacology Division is easy, if you are a
member of ASPET, and would like to be a member of the BPD, please
CLICK HERE.
If you already are a member, please take moment to find your name on the
membership list
to make sure we have up-to-date contact information for you. Thanks! |
Student / post-doc best
poster award winners from the EB '09 meeting
 |
1st place post-doc: Greg T. Collins
(University of Michigan) |
|
2nd place post-doc: Jun-Xu Li (University of
Texas Health Sciences Center at San Antonio) |
|
1st place graduate student: Robert W. Gould
(Wake Forest) |
|
2nd place graduate student: tie between
Jennifer B. Dwyer (University of California - Irvine) and Remy Brim
(University of Michigan) |
EB '09 Programs
Pharmacological Imaging in Behavioral
Pharmacology and Drug Development. Chairs: Leonard L. Howell and
Mike A. Nader
|
Pharmacological MRI in awake rats:
application for drug discovery and development. Chih-Liang Chin,
Abbott Laboratories |
|
Pharmacological MRI studies of the
dopaminergic system in rhesus monkeys. Zhiming Zhang, University of
Kentucky |
|
Functional neuroimaging and cocaine
medication development in nonhuman primates. Leonard L. Howell,
Emory University |
|
PET studies of stimulant drugs in humans.
Joanna S. Fowler, Brookhaven National Laboratories |
Advances in Down Syndrome Neuroscience
Research: Implications for Alzheimer's Disease, Dementias and Other
Cognitive Disorders. Chairs: Tim A. Esbenshade and Alberto Costa
|
Down syndrome: A genetic disorder in
biobehavioral perspective. Lynn Nadel, University of Arizona |
|
Human chromosome 21/Down syndrome gene
function: Implications for cognitive development and Alzheimer's
disease. Kathleen Gardiner, University of Colorado Denver in Aurora |
|
Structural and functional changes at the
synapse associated with Down syndrome and Alzheimer's disease. Craig
C. Garner, Stanford University |
|
Evidence for NMDA receptor dysfunction in
Down Syndrome: implications for a potential pharmacotherapy.
Alberto Costa, University of Colorado Health Sciences Center |
Emerging Approaches to Treatment of Alzheimer's
Disease. Chairs: Randy Strong and Greg A. Gerhardt
|
Current status of treatment of Alzheimer's
and related neurodegenerative diseases. Randy Strong and Greg A.
Gerhardt, University of Texas Health Science Center Barshop
Institute for Longevity & Aging Studies & University of Kentucky |
|
Understanding angiogenic dysregulation in
Alzheimer's disease: opening the door for new therapeutic strategies
in AD. Gregory A. Jicha, University of Kentucky |
|
Pathways of amyloid-beta toxicity:
Potential novel targets for intervention in Alzheimer's disease.
Veronica Galvan, The Buck Institute for Aging Research |
|
The effect of anti-Aß interventions on tau
pathology. Salvatore Oddo, University of Texas Health Science
Center, San Antonio |
|
Steroid hormone receptor signaling and
Alzheimer's disease. Meharvan Singh, University of North Texas
Health Science Center, Fort Worth |
The Role of Insulin and Leptin in Drug Addiction
and Mood. Chairs: Charles P. France and Lynette C. Daws
|
Insulin, leptin, and food reward. Dianne P.
Figlewicz Lattemann, University of Washington Health Science Center |
|
The role of leptin signaling in emotional
behavior. Xin-Yun Lu, University of Texas Health Science Center at
San Antonio |
|
DAT depends on what you eat: Neurochemical
and behavioral effects of amphetamine are dependent on insulin
status. Lynette C. Daws, University of Texas Health Science Center
at San Antonio |
|
The role of leptin on human body weight
regulation, endocrine function, and neurobehavioral outcomes.
Gilberto Paz-Filho, University of Miami School of Medicine |
2008 PB Dews Awardee
 Dr.
Charles Robert Schuster, Professor of Psychiatry and Behavioral
Neurosciences at Wayne State University School of Medicine is the winner
of the 2008 P.B. Dews Lifetime Achievement Award in Behavioral
Pharmacology. The award is given every other year and honors the
fundamental contributions of P.B. Dews to behavioral pharmacology.
Dr. Schuster was presented the P.B. Dews Award at the ASPET Business
Meeting of the Annual Meeting of the American Society for Pharmacology
and Experimental Therapeutics/Experimental Biology (EB) 2008 Meeting in
San Diego, California. His lecture was titled "Contributions of
behavioral pharmacology to our understanding of the etiology, prevention
& treatment of substance abuse."
___________________
News Archive |
